In August, the AIM-listed group reported a phase I/II trial of its live biotherapeutic in combination with established cancer drug Keytruda had “far exceeded” the threshold for success set out before the study began.
4D’s MRx0518 has been developed to work synergistically with Keytruda to re-engage the immune system and stop the effects of the drug wearing off.
Axel Glasmacher, chair, added that 4D pharma had built on its leading position in the live biotherapeutics field over the year.
“We announced proof-of-concept efficacy data in oncology for lead candidate MRx0518, and have made meaningful progress in other important therapeutic areas.
“In concert with this growth, 4D has further expanded both its leadership expertise and its international shareholder base.”
4D pharma had cash and equivalents of £10mln at end June since when it had raised a further £7.7mln.
Losses for the half-year were £13.6mln after R&D spending of £12.4mln.